Literature DB >> 17257236

Occipital nerve stimulation for chronic headache--long-term safety and efficacy.

T J Schwedt1, D W Dodick, J Hentz, T L Trentman, R S Zimmerman.   

Abstract

The aim of this study was to examine the safety and efficacy of occipital nerve stimulation for medically intractable headache. Electrical stimulation of large sensory afferents has an antinociceptive effect. Occipital nerve stimulation may be effective for the treatment of medically intractable headache. Retrospective analysis was performed of 15 patients with medically refractory headache who underwent implantation of an occipital nerve stimulator. Pre- and postimplant data regarding headache frequency, severity, disability, depression and poststimulator complications were collected. Twelve patients were female and three male. Ages ranged from 21 to 52 years (mean 39 years). Eight patients had chronic migraine, three chronic cluster, two hemicrania continua and two had post-traumatic headache. Eight patients underwent bilateral and seven had unilateral lead placement. Patients were measured after 5-42 months (mean 19). All six mean headache measures improved significantly from baseline (P < 0.03). Headache frequency per 90 days improved by 25 days from a baseline of 89 days; headache severity (0-10) improved 2.4 points from a baseline of 7.1 points; MIDAS disability improved 70 points from a baseline of 179 points; HIT-6 scores improved 11 points from a baseline of 71 points; BDI-II improved eight points from a baseline of 20 points; and the mean subjective percent change in pain was 52%. Most patients (60%) required lead revision within 1 year. One patient required generator revision. Occipital nerve stimulation may be effective in some patients with intractable headache. Surgical revisions may be commonly required. Safety and efficacy results from prospective, randomized, sham-controlled studies in patients with medically refractory headache are needed.

Entities:  

Mesh:

Year:  2007        PMID: 17257236     DOI: 10.1111/j.1468-2982.2007.01272.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  53 in total

Review 1.  Occipital nerve stimulation for headache disorders.

Authors:  Koen Paemeleire; Thorsten Bartsch
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

Review 2.  Peripheral neuromodulation in chronic migraine.

Authors:  F Perini; A De Boni
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

3.  Occipital nerve stimulation in primary headache syndromes.

Authors:  Giorgio Lambru; Manjit S Matharu
Journal:  Ther Adv Neurol Disord       Date:  2012-01       Impact factor: 6.570

Review 4.  [Therapeutic neuromodulation in primary headaches].

Authors:  A May; T P Jürgens
Journal:  Nervenarzt       Date:  2011-06       Impact factor: 1.214

5.  Treatment of hemicrania continua by occipital nerve stimulation with a bion device.

Authors:  Julio Pascual
Journal:  Curr Pain Headache Rep       Date:  2009-02

Review 6.  Supratrochlear and Supraorbital Nerve Stimulation for Chronic Headache: a Review.

Authors:  Stephanie Wrobel Goldberg; Stephanie J Nahas
Journal:  Curr Pain Headache Rep       Date:  2015-07

7.  A Materials Roadmap to Functional Neural Interface Design.

Authors:  Steven M Wellman; James R Eles; Kip A Ludwig; John P Seymour; Nicholas J Michelson; William E McFadden; Alberto L Vazquez; Takashi D Y Kozai
Journal:  Adv Funct Mater       Date:  2017-07-19       Impact factor: 18.808

Review 8.  Non-Invasive Neuromodulation for Headache Disorders.

Authors:  Shuhan Zhu; Michael J Marmura
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 5.081

9.  Neurostimulation of the lacrimal nerve for enhanced tear production.

Authors:  Andrea L Kossler; Jianhua Wang; William Feuer; David T Tse
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2015 Mar-Apr       Impact factor: 1.746

Review 10.  Peripheral nerve stimulation for neuropathic pain.

Authors:  Konstantin V Slavin
Journal:  Neurotherapeutics       Date:  2008-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.